Starting January 1, 2025, most Blue Shield commercial members using Fresenius Kabi's adalimumab-aacf (a Humira biosimilar) ...

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax ...

Seven new clinical trial grants were awarded under the Orphan Product Grants Program during the fiscal year (FY) 2024, ...

The month-long standoff between the US Health Resources and Services Administration (HRSA) and Johnson & Johnson came to an ...